Zhengye Biotechnology Holding Limited (ZYBT)
Zhengye Biotechnology Holding will go public soon, but the exact IPO date is still unknown.
IPO Price Range
$4.00 - $5.00
Shares Offered
1,500,000
Deal Size
$6.75M
ZYBT Revenue
Zhengye Biotechnology Holding had revenue of 253.77M CNY in the twelve months ending June 30, 2023. In the year 2022, Zhengye Biotechnology Holding had annual revenue of 260.27M with 21.58% growth.
Revenue (ttm)
253.77M CNY
Revenue Growth
+21.58%
P/S Ratio
5.77
Revenue / Employee
848,729 CNY
Employees
299
Market Cap
212.25M USD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2022 | 260.27M | 46.20M | 21.58% |
| Dec 31, 2021 | 214.07M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionZYBT News
- 11 months ago - Zhengye Biotechnology's Growth Slows As It Seeks U.S. IPO - Seeking Alpha
- 11 months ago - Chinese animal health company Zhengye Biotechnology Holding files for a $20 million US IPO - Renaissance Capital
- 11 months ago - Zhengye Biotechnology IPO Registration Document (F-1) - SEC